Int Urol Nephrol (2017) 49:1691–1697 DOI 10.1007/s11255-017-1615-x NEPHROLOGY – ORIGINAL PAPER In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity 1 1 1 Theodoros Eleftheriadis · Georgios Pissas · Maria Sounidaki · 1 2 1 Georgia Antoniadi · Nikolaos Antoniadis · Vassilios Liakopoulos · Ioannis Stefanidis Received: 12 March 2017 / Accepted: 9 May 2017 / Published online: 15 May 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Results In two-way MLRs, tacrolimus inhibited cell prolif- Purpose Acute cellular rejection is the major cause of eration more than everolimus. In one-way MLRs, tacroli- immune-mediated graft failure early in the course of kid- mus and everolimus decreased alloantibody production to ney transplantation, whereas chronic antibody-mediated the same extent. rejection is a major contributor to graft loss in the late post- Conclusions In human cell cultures, everolimus is infe- transplant phase. Based mainly on the results of short-term rior to tacrolimus in inhibiting cellular alloimmunity, but studies, the calcineurin inhibitor tacrolimus prevails over equally effective as regards humoral alloimmunity. Thus, the mammalian target of rapamycin (mTOR) inhibitors. everolimus might be a safe alternative in case of tacroli- However, the toxicity
International Urology and Nephrology – Springer Journals
Published: May 15, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera